Navigation Links
Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects

NEW YORK (April 29, 2009) -- In searching for a simple way to identify individuals with smoking-related lung injury, scientists at Weill Cornell Medical College have stumbled upon a potential explanation for why the class of pain-relievers known as COX-2 inhibitors increases the risk of heart problems among users.

The findings are notable in two ways, explains Dr. Andrew J. Dannenberg, director of the Weill Cornell Cancer Center and the Henry R. Erle, M.D.Roberts Family Professor of Medicine at Weill Cornell Medical College and a leading gastroenterologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. "Not only could they lead to the development of a simple urine test to determine which smokers are at increased risk of developing chronic obstructive pulmonary disease or emphysema, but they might also pave the way for new drugs or combinations of drugs that harness the benefit of COX-2 inhibitors, including cancer-fighting properties, with reduced cardiovascular toxicity."

Dr. Dannenberg is senior author of a new study detailing the findings which appears in the April issue of Cancer Prevention Research. A collaboration led by Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, the research study was funded by Weill Cornell's Clinical and Translational Science Center (CTSC), an NIH-funded consortium for biomedical collaboration on New York's Upper East Side, as well as by the Flight Attendant Medical Research Institute (FAMRI), Pfizer Inc., and a Memorial Sloan-Kettering Cancer Center Prevention Control and Population Research Program Pilot Project Award.

COX-2 inhibitors were developed to selectively target the cyclooxygenase-2 (COX-2) enzyme, which plays an important role in inflammation. The idea was to treat pain and arthritis without the potentially dangerous gastrointestinal side effects of other non-steroidal anti-inflammatory drugs (NSAIDs). This class of drugs has also been shown to reduce colorectal polyps, a precursor to colorectal cancer. But two blockbuster COX-2 inhibitors, Vioxx (rofecoxib) and Bextra (valdecoxib), were pulled off the market after reports that they elevated the risk of heart attack, stroke and death in users. Celebrex (celecoxib) is the only COX-2 inhibitor still available.

The current trial was originally designed to identify biomarkers in urine which could indicate the presence of incipient, smoking-related lung disease. The researchers had hypothesized that early-stage lung injury could "turn on" the COX-2 gene, increasing levels of the major prostaglandin metabolite PGE-M in the urine.

In addition to determining PGE-M levels, the investigators also looked at levels of the biomarker leukotriene E4 (LTE4), formed by the 5-lipoxygenase (5-LO) pathway. Both biomarkers, representing these two different pathways, are synthesized from arachidonic acid. The 5-LO pathway has also been implicated in inflammation, cancer and cardiovascular problems.

For this study, 28 never-smokers, 26 former smokers and 28 current smokers took 200 milligrams of Celebrex twice a day for about a week. At the beginning of the study, current smokers had higher levels of both PGE-M and LTE4 than never-smokers. High PGE-M levels suggest higher levels of COX-2 activity. Twice-daily doses of Celebrex resulted in reduced PGE-M levels in all three groups, with the largest drop seen among those who had high starting levels of PGE-M.

"But we also found that Celebrex treatment led to increases in urinary LTE4 levels, primarily among individuals who had started out with high PGE-M levels," says first author Dr. Anna J. Duffield-Lillico, a consultant with the Department of Epidemiology and Biostatistics and the Department of and Surgery at Memorial Sloan-Kettering Cancer Center. "This indicated that Celebrex 'shunted' or redirected arachidonic acid into the 5-LO pathway from the COX pathway. When one went down, the other went up." This is important because other studies have suggested an important role for the 5-LO pathway in atherosclerosis, heart attacks and stroke.

And it is this increased shunting of arachidonic acid into the 5-LO pathway that may help explain why COX-2 inhibitors contribute to cardiovascular problems, the researchers say.

"More studies are needed to see if these two biomarkers are reliable indicators of the presence of low-level lung inflammation," notes Dr. Dannenberg.

And more research is necessary to understand the role of COX-2 inhibitors in the heart, especially to see if their anti-cancer effects can be attained without the counterbalancing negative effects.


Contact: Andrew Klein
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College

Related medicine news :

1. General Public and Physicians Express Similar Levels of Concern Regarding Potential Swine Flu Pandemic
2. Potential preventative therapy for Type 1 diabetes
3. Hormone therapy offers potential protective effect against colon cancer in older women
4. Commonly used ulcer drugs may offer treatment potential in Alzheimers disease
5. Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population
6. As Global Recession Worsens, is Malaria Killing Africas Potential?
7. A potential new target for treatment of hormone refractory prostate cancer
8. Arthritis Trial Leads to Potential Cure for High Blood Pressure
9. Spotlight Baby Provides Parents with Educational Programs and Eco-Friendly Products to Support Babies in Reaching Their Full Developmental Potentials
10. Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar
11. Next Generation Optical Technology Has Potential to Greatly Improve Patient Safety
Post Your Comments:
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: